These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 19414683)

  • 1. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
    Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J
    J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
    Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
    Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
    Kimura H; Suminoe M; Kasahara K; Sone T; Araya T; Tamori S; Koizumi F; Nishio K; Miyamoto K; Fujimura M; Nakao S
    Br J Cancer; 2007 Sep; 97(6):778-84. PubMed ID: 17848912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.
    Hu W; Liu Y; Chen J
    Oncotarget; 2017 Apr; 8(15):25046-25054. PubMed ID: 28212572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.
    Sutiman N; Tan SW; Tan EH; Lim WT; Kanesvaran R; Ng QS; Jain A; Ang MK; Tan WL; Toh CK; Chowbay B
    J Thorac Oncol; 2017 Mar; 12(3):529-538. PubMed ID: 27908825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
    Taron M; Ichinose Y; Rosell R; Mok T; Massuti B; Zamora L; Mate JL; Manegold C; Ono M; Queralt C; Jahan T; Sanchez JJ; Sanchez-Ronco M; Hsue V; Jablons D; Sanchez JM; Moran T
    Clin Cancer Res; 2005 Aug; 11(16):5878-85. PubMed ID: 16115929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.
    Zhou Q; Zhang XC; Chen ZH; Yin XL; Yang JJ; Xu CR; Yan HH; Chen HJ; Su J; Zhong WZ; Yang XN; An SJ; Wang BC; Huang YS; Wang Z; Wu YL
    J Clin Oncol; 2011 Aug; 29(24):3316-21. PubMed ID: 21788562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
    Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
    Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment.
    Que D; Xiao H; Zhao B; Zhang X; Wang Q; Xiao H; Wang G
    Cancer Biol Ther; 2016; 17(3):320-7. PubMed ID: 26785777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
    Wang Z; Wu YL; Zhang GC; Zhou Q; Xu CR; Guo AL
    Onkologie; 2008 Apr; 31(4):174-8. PubMed ID: 18418018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
    Baty F; Rothschild S; Früh M; Betticher D; Dröge C; Cathomas R; Rauch D; Gautschi O; Bubendorf L; Crowe S; Zappa F; Pless M; Brutsche M;
    PLoS One; 2013; 8(9):e72966. PubMed ID: 24039832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
    Locatelli-Sanchez M; Couraud S; Arpin D; Riou R; Bringuier PP; Souquet PJ
    Lung; 2013 Oct; 191(5):491-9. PubMed ID: 23749122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.
    Yin YM; Geng YT; Shao YF; Hu XL; Li W; Shu YQ; Wang ZX
    J Exp Clin Cancer Res; 2010 Sep; 29(1):126. PubMed ID: 20843324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status.
    Duan H; Lu J; Lu T; Gao J; Zhang J; Xu Y; Wang M; Wu H; Liang Z; Liu T
    Int J Clin Exp Pathol; 2015; 8(10):13136-45. PubMed ID: 26722512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
    Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
    J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.